Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel method of diagnosing, monitoring, staging, imaging and treating various cancers

a cancer and imaging technology, applied in the field of gynecologic cancer, can solve the problem that the pelvis is at a higher risk of developing sarcoma of the uterus

Inactive Publication Date: 2005-07-21
SALCEDA SUSANA +3
View PDF12 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012] Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the selected cancer. For the purposes of this invention, by “selected cancer” it is meant to include gynecologic cancers such as ovarian, breast, endometrial and uterine cancer, and lung cancer.

Problems solved by technology

However, breast cancer is the leading cause of death in women between the ages of 40 and 55.
Women who have received therapy with high-dose X-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0046] Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte Pharmaceuticals, Palo Alto, Calif., using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, Calif.

[0047] The CLASP performs the following steps: selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs; analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease. Selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor libraries. The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the CSGs selection.

TABLE 1CSG SequencesSEQ ID NO:Clone IDGene ID1166...

example 2

Relative Quantitation of Gene Expression

[0049] Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5′-3′ nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5′ reporter dye and a downstream, 3′ quencher dye. During PCR, the 5′-3′ nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, Calif., USA).

[0050] Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
paramagneticaaaaaaaaaa
oat shapeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.

Description

FIELD OF THE INVENTION [0001] This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating various cancers, particularly gynecologic cancer including ovarian, uterine endometrial and breast cancer, and lung cancer. BACKGROUND OF TEE INVENTION [0002] The American Cancer Society has estimated that over 560,000 Americans will die this year from cancer. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. It has been estimated that over one million new cancer cases will be diagnosed in 1999 alone. [0003] In women, gynecologic cancers account for more than one-fourth of the malignancies. [0004] Of the gynecologic cancers, breast cancer is the most common. According to the Women's Cancer Network, 1 out of every 8 women in the United States is as risk of developing breast cancer, and 1 out of every 28 women are at risk of dying from breast cancer. Approximately 7...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/53A61K39/395A61K49/00A61K51/00A61P35/00A61P35/04C07K16/30C07K16/32C12N15/09C12Q1/68G01N33/574H01M4/86H01M8/02H01M8/10H01M8/24
CPCC12Q1/6886C12Q2600/158G01N33/57411Y10T29/49108G01N33/57442G01N33/57449C12Q2600/16G01N33/57415A61P35/00A61P35/04A61P43/00
Inventor SALCEDA, SUSANASUN, YONGMINGRECIPON, HERVECAFFERKEY, ROBERT
Owner SALCEDA SUSANA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products